[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies]. [electronic resource]
Producer: 20131105Description: 266-73 p. digitalISSN:- 0151-9638
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antineoplastic Agents -- adverse effects
- Benzamides -- adverse effects
- Cetuximab
- Dasatinib
- ErbB Receptors -- antagonists & inhibitors
- Humans
- Imatinib Mesylate
- Indazoles
- Indoles -- adverse effects
- Ipilimumab
- Niacinamide -- adverse effects
- Phenylurea Compounds -- adverse effects
- Pigmentation Disorders -- chemically induced
- Piperazines -- adverse effects
- Piperidines -- adverse effects
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Protein Kinase Inhibitors -- adverse effects
- Pyrimidines -- adverse effects
- Pyrroles -- adverse effects
- Quinazolines -- adverse effects
- Receptors, Vascular Endothelial Growth Factor -- antagonists & inhibitors
- Sorafenib
- Sulfonamides -- adverse effects
- Sunitinib
- Thiazoles -- adverse effects
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.